Fig. 1From: PCSK9 inhibitors for secondary prevention in patients with cardiovascular diseases: a bayesian network meta-analysisSummary of the primary efficacy outcome. A Network plot of all-cause mortality. The width of the lines is proportional to the number of studies comparing every pair of treatments, and the size of each circle is proportional to the number of participants. B The forest plot shows the risk ratio (RR) and credible interval (CrI). C SUCRA-based ranking probabilities graph of each medication. The SUCRA values for each treatment were as follows: 91% for alirocumab; 24% for evolocumab; 44% for inclisiran. SUCRA surface under the cumulative ranking curveBack to article page